.jpg "Madrigal Pharmaceuticals Inc (NASDAQ: MDGL)")
Yesterday, the CEO of Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), Paul A. Friedman, sold shares of MDGL for $21.14M.
In addition to Paul A. Friedman, 4 other MDGL executives reported Sell trades in the last month. This is Friedman’s first transaction since reporting a Sell transaction on INCY back in November 2017
See today’s analyst top recommended stocks >>
The Company has a Price to Book ratio of 22.7381. Currently, Madrigal Pharmaceuticals Inc has an average volume of 562.6K.
Based on 7 analyst ratings, the analyst consensus is Strong Buy with an average price target of $321.17, reflecting a -12.0% downside. One of the top 25 analysts, according to TipRanks.com, recently recommended Buy MDGL with a $400 price target.
In the last 30 days, insiders have sold $180.4M worth of MDGL shares and purchased $22.83M worth of MDGL shares.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia.
Read More on MDGL:
